05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
17:02 , May 25, 2018 |  BC Week In Review  |  Clinical News

MiNA reports preliminary Phase I data for liver cancer candidate

MiNA Therapeutics Ltd. (London, U.K.) reported preliminary data from 10 evaluable patients with advanced hepatocellular carcinoma (HCC) in the Phase I OUTREACH trial showing that once-weekly IV MTL-CEBPA led to one partial response with a...
18:07 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Patient sample and mouse experiments suggest that inhibiting CEBPB could help treat AD. In postmortem brain tissue samples from patients, levels of CEBPB were higher than in samples from unaffected subjects....
21:28 , Nov 10, 2017 |  BC Week In Review  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop therapeutics to treat fibrotic liver disease using MiNA’s small activating RNA (saRNA) technology. The partners' deal is worth up to €307...
23:48 , Nov 8, 2017 |  BC Extra  |  Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology in a deal worth up to €307 million ($355.7...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A profile containing a nine-gene signature in tumors and FCER1B protein levels in tumor mast cells could help predict survival in lung cancer. In 1,225 non-small cell lung cancer (NSCLC) patients, transcriptomic analysis...
01:38 , May 5, 2017 |  BC Week In Review  |  Company News

Sosei gets option to acquire MiNA

Sosei Group Corp. (Tokyo:4565) invested £35 million ($45.2 million) in small activating RNA company MiNA Therapeutics Ltd. (London, U.K.) in exchange for a 25.6% equity stake and an exclusive option to acquire the company. In the...
18:42 , May 3, 2017 |  BC Extra  |  Company News

Sosei invests in MiNA, gets option to acquire

Sosei Group Corp. (Tokyo:4565) invested £35 million ($45.2 million) in small activating RNA company MiNA Therapeutics Ltd. (London, U.K.) in exchange for a 25.6% equity stake and an exclusive option to acquire the company. In the...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BMI1 polycomb ring finger oncogene (BMI1); CCAAT enhancer binding protein α (CEBPA)

Cancer INDICATION: Non-small cell lung cancer (NSCLC) Patient sample, cell culture and mouse studies suggest inhibiting BMI1 could help treat NSCLC patients who have low tumor levels of CEBPA. In NSCLC patients with low tumor levels...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 4 (CDK4); CCAAT enhancer binding protein α (CEBPA)

Hepatic disease INDICATION: Liver disease Patient sample and mouse studies suggest CDK4 inhibitors could help treat non-alcoholic fatty liver disease (NAFLD). In patient liver tissue samples, CDK4 levels were higher than in samples from healthy volunteers. In...